东亚药业(605177.SH)发布上半年业绩，由盈转亏至3022.83万元

Core Viewpoint - Dongya Pharmaceutical (605177.SH) reported a significant decline in performance for the first half of 2025, transitioning from profit to a net loss of 30.23 million yuan due to decreased demand for β-lactam antibiotics [1] Financial Performance - The company's operating revenue for the first half of 2025 was 416 million yuan, representing a year-on-year decrease of 35.85% [1] - The net loss attributable to shareholders was 30.23 million yuan, with a net loss of 35.88 million yuan after excluding non-recurring gains and losses [1] - Basic loss per share was reported at 0.26 yuan [1] Market Factors - The decline in revenue was primarily attributed to reduced demand from downstream customers for β-lactam antibiotics during the reporting period [1]